阿柏西普与曲安奈德治疗非缺血性CRVO继发黄斑水肿的疗效比较  

Comparison of Efficacy Between Aflibercept and Triamcinolone Acetonide in Treatment of Macular Edema Secondary to Non-Ischemic Central Retinal Vein Occlusion

作　　者：张乘瑞 要国欢 焦瑞雪 韩月圣 Zhang Chengrui;Yao Guohuan;Jiao Ruixue;Han Yuesheng(Department of Ophthalmology,Beijing Nuclear Industry Hospital,Beijing 102413 China)

机构地区：[1]北京核工业医院眼科,北京102413

出　　处：《锦州医科大学学报》2021年第2期63-66,共4页Journal of Jinzhou Medical University

摘　　要：目的比较玻璃体腔注射阿柏西普与曲安奈德(triamcinolone acetonide,TA)治疗非缺血性视网膜中央静脉阻塞(central retinal vein occlusion,CRVO)继发黄斑水肿的疗效及安全性。方法采用临床回顾性分析研究,纳入确诊为非缺血性CRVO继发黄斑水肿患者56例56眼,患者被分为2组进行玻璃体腔注射阿柏西普2 mg(0.05 mL)或TA 2 mg(0.05 mL)治疗。每组28例28眼。分别于注射前和注射后1、2、3个月进行复查。比较治疗前和治疗后1个月、2个月、3个月两组间和各组内部的最佳矫正视力(best corrected visual acuity,BCVA)和黄斑中心凹视网膜厚度(central macular thickness,CMT)的改变。结果阿柏西普组和TA组玻璃体腔注射后1个月、2个月BCVA均明显优于注射前,差异均有统计学意义;3个月时BCVA与注射前比较差异无统计学意义。阿柏西普组和TA组玻璃体腔注射后1个月、2个月CMT值较注射前均明显下降,差异均有统计学意义,3个月时CMT与注射前比较差异无统计学意义;两组间BCVA在1个月(t=0.405,P=0.687)、2个月(t=0.361,P=0.719)、3个月(t=0.257,P=0.798)时均无统计学意义(P>0.05);两组间CMT在1个月(t=-0.543,P=0.589)、2个月(t=-0.607,P=0.546)、3个月(t=-0.384,P=0.703)时均无统计学意义(P>0.05)。治疗后眼压明显升高仅见于TA组。结论玻璃体腔注射阿柏西普及曲安奈德治疗非缺血性CRVO所致黄斑水肿均有效,能显著提高视力,减轻黄斑水肿。与TA相比,阿柏西普副作用更小更加安全可靠。Objective To compare the effect and safety of intravitreal injection of aflibercept and triamcinolone acetonide(TA)in the treatment of macular edema secondary to non-ischemic central retinal vein occlusion(CRVO).Methods Clinical retrospective analysis was conducted in analyzing 56 patients(56 eyes)who were diagnosed as macular edema secondary to non-ischemic CRVO.They were divided into two groups and treated with intravitreal injection of aflibercept or TA for 2 mg(0.05 mL),with 28 cases(28 eyes)in each group.Reexamination was performed before injection and 1,2,and 3 months after injection.The changes in the best corrected visual acuity(BCVA)and central macular thickness(CMT)were compared between the two groups and within each group before and 1,2 and 3 months after treatment.Results BCVA 1 month and 2 months after intravitreous injection was significantly better than that before injection in both the aflibercept group and the TA group,with statistically significant difference.There was no statistically significant difference in BCVA 3 months after injection and that before injection.CMT value of the aflibercept group and the TA group decreased significantly 1 month and 2 months after intravitreal injection compared with that before injection,with statistically significant difference.There was no statistically significant difference in CMT 3 months after injection and that before injection.No statistically significant difference was found in BCVA between the two groups 1 month(t=0.405,P=0.687),2 months(t=0.361,P=0.719)and 3 months(t=0.257,P=0.798)(P>0.05)after injection.No statistically significant difference was shown in CMT between the two groups 1 month(t=-0.543,P=0.589),2 months(t=-0.607,P=0.546)and 3 months(t=-0.384,P=0.703)after injection(P>0.05).Significant increase of intraocular pressure after treatment was found only in the TA group.Conclusion Intravitreal injection of aflibercept and triamcinolone acetonide are both effective in the treatment of macular edema caused by non-ischemic CRVO,which can signi

关 键 词：阿柏西普 曲安奈德 视网膜静脉阻塞 黄斑水肿 

分 类 号：R774.5[医药卫生—眼科]